310 related articles for article (PubMed ID: 35347591)
21. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.
Eskander RN
Am Soc Clin Oncol Educ Book; 2018 May; 38():480-487. PubMed ID: 30231335
[TBL] [Abstract][Full Text] [Related]
22. Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Tomao F; Santangelo G; Musacchio L; Di Donato V; Fischetti M; Giancotti A; Perniola G; Petrella MC; Monti M; Palaia I; Muzii L; Benedetti Panici P
J Cell Physiol; 2020 Jun; 235(6):5050-5058. PubMed ID: 31912897
[TBL] [Abstract][Full Text] [Related]
23. Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3.
Lee JY; Lee YY; Park JY; Shim SH; Kim SI; Kong TW; Lim CK; Cho HW; Suh DH
J Gynecol Oncol; 2023 Mar; 34(2):e51. PubMed ID: 36890294
[TBL] [Abstract][Full Text] [Related]
24. Major clinical research advances in gynecologic cancer in 2017.
Suh DH; Kim M; Lee KH; Eom KY; Kjeldsen MK; Mirza MR; Kim JW
J Gynecol Oncol; 2018 Mar; 29(2):e31. PubMed ID: 29468855
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.
Reyes HD; Thiel KW; Carlson MJ; Meng X; Yang S; Stephan JM; Leslie KK
Mol Diagn Ther; 2014 Apr; 18(2):137-51. PubMed ID: 24403167
[TBL] [Abstract][Full Text] [Related]
26. Metastatic gynecologic malignancies: advances in treatment and management.
Chan JK; Chow S; Bhowmik S; Mann A; Kapp DS; Coleman RL
Clin Exp Metastasis; 2018 Aug; 35(5-6):521-533. PubMed ID: 29931499
[TBL] [Abstract][Full Text] [Related]
27. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
28. Major clinical research advances in gynecologic cancer in 2021.
Park JY; Lee JY; Lee YY; Shim SH; Suh DH; Kim JW
J Gynecol Oncol; 2022 Mar; 33(2):e43. PubMed ID: 35245004
[TBL] [Abstract][Full Text] [Related]
29. [The opportunities and challenges of gynecologic cancer in precision medicine].
Ma D
Zhonghua Yi Xue Za Zhi; 2022 Jul; 102(26):1963-1966. PubMed ID: 35817720
[TBL] [Abstract][Full Text] [Related]
30. Major clinical research advances in gynecologic cancer in 2015.
Suh DH; Kim M; Kim HJ; Lee KH; Kim JW
J Gynecol Oncol; 2016 Nov; 27(6):e53. PubMed ID: 27775259
[TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Le Saux O; Vanacker H; Guermazi F; Carbonnaux M; Roméo C; Larrouquère L; Trédan O; Ray-Coquard I
Future Oncol; 2021 Jun; 17(18):2291-2304. PubMed ID: 33726504
[TBL] [Abstract][Full Text] [Related]
32. [Minimally invasive treatment of gynecologic cancers].
Ichikawa Y; Yoshikawa H
Gan To Kagaku Ryoho; 2001 Aug; 28(8):1090-3. PubMed ID: 11525023
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Kotsopoulos IC; Kucukmetin A; Mukhopadhyay A; Lunec J; Curtin NJ
Int J Gynecol Cancer; 2016 May; 26(4):763-9. PubMed ID: 26905326
[TBL] [Abstract][Full Text] [Related]
34. PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
Crafton SM; Bixel K; Hays JL
Gynecol Oncol; 2016 Sep; 142(3):588-96. PubMed ID: 27168003
[TBL] [Abstract][Full Text] [Related]
35. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Ratner ES; Sartorelli AC; Lin ZP
Curr Opin Oncol; 2012 Sep; 24(5):564-71. PubMed ID: 22759740
[TBL] [Abstract][Full Text] [Related]
36. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
37. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
Bieńkowski M; Tomasik B; Braun M; Jassem J
Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
[TBL] [Abstract][Full Text] [Related]
38. International Gynecologic Cancer Society (IGCS) 2016: Meeting report.
Del Carmen MG; Rice LW
Gynecol Oncol; 2017 Jan; 144(1):11-15. PubMed ID: 27847107
[No Abstract] [Full Text] [Related]
39. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
[TBL] [Abstract][Full Text] [Related]
40. Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.
Suh DH; Kim M; Kim K; Kim HJ; Lee KH; Kim JW
J Gynecol Oncol; 2017 May; 28(3):e45. PubMed ID: 28382802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
